Sign in
CompletedPhase 2

Propranolol for Sleep Apnea Therapy

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
24 people enrolled
Started
15 Feb 2017
Ended
1 May 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Propranolol Oral Tablet
  • Placebo Oral Tablet
Record updated
5 September 2024

Who can take part

Age
20 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • History of OSA (AHI>20, >50% events obstructive)
  • Accustomed to CPAP use, and willing to discontinue CPAP temporarily for the study
  • If the participant has already completed "Metabolic Impact of Intermittent CPAP" (NA_00086830), they must have exhibited a >10% increase in nocturnal FFA or glucose during CPAP

Who cannot take part

  • Cardiovascular risks; Decompensated congestive heart failure; Atrial fibrillation, sick sinus syndrome, 2nd or 3rd degree heart block, pacemaker implantation, Wolff-Parkinson-White Syndrome (if not known, will check on a screening EKG); Uncontrolled hypertension > 170/110; History of postural hypotension; Resting systolic pressure <90 or heart rate < 50 on screening visit
  • History of falling asleep while driving, near miss
  • Drug interactions - currently taking any of the following drugs. (Subjects on these medications are excluded from participation and will not have the drug in question discontinued for the purposes of participation in the study. ); Calcium channel blockers that reduce heart rate (diltiazem, verapamil, fendiline, gallopamil); Sympatholytic drugs: any other beta blocker; clonidine, terazosin or doxazosin; reserpine; Anti-arrhythmic drugs: (e.g. amiodarone, sotalol, digoxin, quinidine, lidocaine, propafenone); Coumadin (propranolol may prolong INR); Drugs that Inhibit CYP2D6, CYP1A2, or CYP2C19: amiodarone, ciprofloxacin, cimetidine, delavirdine, fluconazole, fluoxetine, fluvoxamine, imipramine, isoniazid, paroxetine, quinidine, ritonavir, rizatriptan, teniposide, theophylline, tolbutamide, zileuton, zolmitriptan; Drugs that increase hepatic metabolism of propranolol: rifampin, ethanol, phenytoin, and phenobarbital; Neuroleptics/anxiolytics: (thioridazine, chlorpromazine - may increase propranolol level), haloperidol, valium; Illicit drugs such as cocaine or amphetamines
  • High risk occupation (pilot, commercial driver) Hemoglobin < 10 g/dL on point of care screening
  • Other medical conditions; Sleep disorder other than OSA, including: restless leg syndrome, parasomnia, or narcolepsy; Shift work or circadian rhythm disorder that is expected to prevent good sleep as scheduled in the protocol; Insulin-dependent diabetes mellitus; Myasthenia gravis; Pheochromocytoma; Uncontrolled bronchospastic lung disease such as asthma or chronic obstructive pulmonary disease (COPD); Current smoking; Chronic renal or liver failure; Known pregnancy, by urine testing in women of child-bearing age; nursing mothers; Known hypersensitivity to any beta blocker

Where in United States

  • Johns Hopkins Bayview Medical CenterBaltimore, United States

About the trial

What the trial wants to find out

The primary objective of this study is to test whether a beta blocker, propranolol, lowers the overnight heart rate sleep in obstructive sleep apnea (OSA) during CPAP withdrawal. The secondary objectives are to test whether propranolol influences sleep architecture, morning blood pressure, and vascular function including reactive hyperemia index (RHI) and a marker of arterial stiffness, augmentation index (AIX).

The 2 groups in the trial

  • Placebo Oral TabletPlacebo, for comparison

    Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, placebo of propranolol LA (Inderal ® LA) 80 mg will be administered orally at 6:30 PM, after dinner. Blood pressure will be measured before administration, at 10:30 PM, and 6:30 AM. They will sleep from 10:30 PM to 6:30 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will is crossed-over with active drug 1 week before or after this study night.

    Treatment: Propranolol Oral Tablet and Placebo Oral Tablet

  • Propranolol Oral TabletExisting treatment, for comparison

    Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 6:30 PM, after dinner. Blood pressure will be measured before administration, at 10:30 PM, and 6:30 AM. They will sleep from 10:30 Pm to 6:30 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will be crossed-over to placebo 1 week later. This arm will is crossed-over with active drug 1 week before or after this study night.

    Treatment: Propranolol Oral Tablet and Placebo Oral Tablet

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
5 September 2024